Phase II study of cytarabine in Hodgkin's disease

José Thomas, Ben de Pauw, Anton Hagenbeek, Reinier Somers, Patrice Carde, Umberto Tirelli, Nicole Duez

Research output: Contribution to journalArticlepeer-review


Cytarabine was administered to 24 patients with previously treated Hodgkin's disease in the EORTC Lymphoma Cooperative Group. The drug was administered at the dose of 80 mg/m2 subcutaneously twice a day on 5 consecutive days every 3 weeks. The overall response rate was 17.6% (3 responses among 17 evaluable patients) with a short duration (2-6 months). The main toxicity was myelosuppression. Our experience in the EORTC Lymphoma Cooperative Group could not demonstrate a significant activity at this dose and schedule in Hodgkin's disease.

Original languageEnglish
Pages (from-to)857-859
Number of pages3
JournalEuropean Journal of Cancer
Issue number4-5
Publication statusPublished - 1992

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology


Dive into the research topics of 'Phase II study of cytarabine in Hodgkin's disease'. Together they form a unique fingerprint.

Cite this